Micro-CT-assisted identification of the optimal time-window for antifibrotic treatment in a bleomycin mouse model of long-lasting pulmonary fibrosis

• Published in: Scientific reports 2024-06, Vol.14 (1), p.14792-14, Article 14792
• Main Authors: Buccardi, Martina, Grandi, Andrea, Ferrini, Erica, Buseghin, Davide, Villetti, Gino, Civelli, Maurizio, Sverzellati, Nicola, Aliverti, Andrea, Pennati, Francesca, Stellari, Franco Fabio
• Format: Article
• Language: English
• Subjects: 631/154; 692/308/1426; 692/308/2778; Animal models; Animals; Antifibrotic Agents - pharmacology; Antifibrotic Agents - therapeutic use; Bleomycin; Bleomycin - adverse effects; Bleomycin model; Bronchus; Computed tomography; Disease Models, Animal; Drug discovery; Fibrosis; Functional measurements; Histology; Humanities and Social Sciences; Idiopathic Pulmonary Fibrosis - chemically induced; Idiopathic Pulmonary Fibrosis - diagnostic imaging; Idiopathic Pulmonary Fibrosis - drug therapy; Idiopathic Pulmonary Fibrosis - pathology; Indoles - pharmacology; Indoles - therapeutic use; Inflammation; IPF; Lavage; Lung - diagnostic imaging; Lung - drug effects; Lung - pathology; Lung diseases; Lung fibrosis; Mice; Mice, Inbred C57BL; Micro-computed tomography; Morphology; multidisciplinary; Pulmonary fibrosis; Pulmonary Fibrosis - chemically induced; Pulmonary Fibrosis - diagnostic imaging; Pulmonary Fibrosis - drug therapy; Pulmonary Fibrosis - pathology; Respiratory function; Science; Science (multidisciplinary); Side effects; Structure-function relationships; Time Factors; X-Ray Microtomography
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-65030-3

Idiopathic Pulmonary Fibrosis (IPF) is a debilitating and fatal lung disease characterized by the excessive formation of scar tissue and decline of lung function. Despite extensive research, only two FDA-approved drugs exist for IPF, with limited efficacy and relevant side effects. Thus, there is an urgent need for new effective therapies, whose discovery strongly relies on IPF animal models. Despite some limitations, the Bleomycin (BLM)-induced lung fibrosis mouse model is widely used for antifibrotic drug discovery and for investigating disease pathogenesis. The initial acute inflammation triggered by BLM instillation and the spontaneous fibrosis resolution that occurs after 3 weeks are the major drawbacks of this system. In the present study, we applied micro-CT technology to a longer-lasting, triple BLM administration fibrosis mouse model to define the best time-window for Nintedanib (NINT) treatment. Two different treatment regimens were examined, with a daily NINT administration from day 7 to 28 (NINT 7–28), and from day 14 to 28 (NINT 14–28). For the first time, we automatically derived both morphological and functional readouts from longitudinal micro-CT. NINT 14–28 showed significant effects on morphological parameters after just 1 week of treatment, while no modulations of these biomarkers were observed during the preceding 7–14-days period, likely due to persistent inflammation. Micro-CT morphological data evaluated on day 28 were confirmed by lung histology and bronchoalveolar lavage fluid (BALF) cells; Once again, the NINT 7–21 regimen did not provide substantial benefits over the NINT 14–28. Interestingly, both NINT treatments failed to improve micro-CT-derived functional parameters. Altogether, our findings support the need for optimized protocols in preclinical studies to expedite the drug discovery process for antifibrotic agents. This study represents a significant advancement in pulmonary fibrosis animal modeling and antifibrotic treatment understanding, with the potential for improved translatability through the concurrent structural–functional analysis offered by longitudinal micro-CT.